{"id":483076,"date":"2021-04-28T07:05:11","date_gmt":"2021-04-28T11:05:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/"},"modified":"2021-04-28T07:05:11","modified_gmt":"2021-04-28T11:05:11","slug":"valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/","title":{"rendered":"Valeo Pharma&#8217;s Redesca\u00ae and Redesca HP\u00ae to Be Covered Under the Ontario Public Drug Benefit Program"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>\n          <b><br \/>\n            <span class=\"xn-location\">Ontario<\/span> represents 37% of the Canadian low molecular weight heparin market<\/b>\n        <\/li>\n<li>\n          <b>Additional provincial coverage expected to follow <\/b><br \/>\n          \n        <\/li>\n<\/ul>\n<p>\n        <span class=\"xn-location\">MONTREAL<\/span>, <span class=\"xn-chron\">April 28, 2021<\/span> \/PRNewswire\/ &#8211; <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3144448-1&amp;h=2763238022&amp;u=https%3A%2F%2Fwww.valeopharma.com%2F&amp;a=Valeo+Pharma+Inc\" rel=\"nofollow noopener\">Valeo Pharma Inc<\/a>. (CSE: VPH)\u00a0(OTCQB: VPHIF)\u00a0(FSE: VP2) (&#8220;<b>Valeo<\/b>&#8221; or the &#8220;<b>Company<\/b>&#8220;), a Canadian pharmaceutical company, today announced that it has entered into a Product Listing Agreement (&#8220;PLA&#8221;) with the Executive Officer of the Ontario Public Drug Program for the listing of\u00a0Redesca<b>\u00ae<\/b>\u00a0and Redesca HP<b>\u00ae<\/b>, its low molecular weight heparin (&#8220;LMWH&#8221;) biosimilar, on the Ontario Drug Benefit Formulary effective <span class=\"xn-chron\">April 30, 2021<\/span>. \u00a0<\/p>\n<p>&#8220;With <span class=\"xn-location\">Ontario<\/span> representing 37% of the Canadian market for LMWHs, the listing of Redesca on the <span class=\"xn-location\">Ontario<\/span> public formulary is a key milestone for the Redesca commercialization program&#8221;, said <span class=\"xn-person\">Frederic Fasano<\/span>, President and COO of Valeo. &#8220;This is welcome news for millions of Canadians who rely on public insurance to access their prescription medications and for the Government of <span class=\"xn-location\">Ontario<\/span> who will benefit from significant savings resulting from the listing of the first LMWH biosimilar. We anticipate additional provincial coverage will follow&#8221;, added Mr. Fasano. <\/p>\n<p>\n        <b>About Redesca, Redesca HP<\/b>\n      <\/p>\n<p>Redesca is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. Redesca has more than 8 years of proven in-market safety internationally and more than 150 million patient days treated in <span class=\"xn-location\">Europe<\/span> alone.<\/p>\n<p>\n        <b>About Valeo Pharma <\/b>\n      <\/p>\n<p>Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in <span class=\"xn-location\">Canada<\/span> with a focus on Respiratory, Neurology, Oncology and Hospital Specialty Products. Headquartered in <span class=\"xn-location\">Kirkland, Quebec<\/span> Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit <b><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3144448-1&amp;h=3541736322&amp;u=http%3A%2F%2Fwww.valeopharma.com%2F&amp;a=www.valeopharma.com\" rel=\"nofollow noopener\">www.valeopharma.com<\/a><\/b><b>\u00a0<\/b>and follow us on <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3144448-1&amp;h=3985500628&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fvaleo-pharma&amp;a=LinkedIn\" rel=\"nofollow noopener\"><b>LinkedIn<\/b><\/a>\u00a0and <b><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3144448-1&amp;h=3938105749&amp;u=https%3A%2F%2Ftwitter.com%2Fvaleo_pharma%3Flang%3Den&amp;a=Twitter\" rel=\"nofollow noopener\">Twitter<\/a><\/b><b>.<\/b><\/p>\n<p>\n        <b>Forward Looking Statements<\/b>\n      <\/p>\n<p>This press release contains forward-looking statements about Valeo&#8217;s objectives, strategies and businesses that involve risks and uncertainties. These statements are &#8220;forward-looking&#8221; because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. <\/p>\n<p>NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. <\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO58339&amp;sd=2021-04-28\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program-301278586.html\">http:\/\/www.prnewswire.com\/news-releases\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program-301278586.html<\/a><\/p>\n<p>SOURCE  Valeo Pharma Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=MO58339&amp;Transmission_Id=202104280700PR_NEWS_USPR_____MO58339&amp;DateId=20210428\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Ontario represents 37% of the Canadian low molecular weight heparin market Additional provincial coverage expected to follow MONTREAL, April 28, 2021 \/PRNewswire\/ &#8211; Valeo Pharma Inc. (CSE: VPH)\u00a0(OTCQB: VPHIF)\u00a0(FSE: VP2) (&#8220;Valeo&#8221; or the &#8220;Company&#8220;), a Canadian pharmaceutical company, today announced that it has entered into a Product Listing Agreement (&#8220;PLA&#8221;) with the Executive Officer of the Ontario Public Drug Program for the listing of\u00a0Redesca\u00ae\u00a0and Redesca HP\u00ae, its low molecular weight heparin (&#8220;LMWH&#8221;) biosimilar, on the Ontario Drug Benefit Formulary effective April 30, 2021. \u00a0 &#8220;With Ontario representing 37% of the Canadian market for LMWHs, the listing of Redesca on the Ontario public formulary is a key milestone for the Redesca commercialization program&#8221;, said Frederic Fasano, President and COO &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Valeo Pharma&#8217;s Redesca\u00ae and Redesca HP\u00ae to Be Covered Under the Ontario Public Drug Benefit Program&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-483076","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Valeo Pharma&#039;s Redesca\u00ae and Redesca HP\u00ae to Be Covered Under the Ontario Public Drug Benefit Program - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valeo Pharma&#039;s Redesca\u00ae and Redesca HP\u00ae to Be Covered Under the Ontario Public Drug Benefit Program - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Ontario represents 37% of the Canadian low molecular weight heparin market Additional provincial coverage expected to follow MONTREAL, April 28, 2021 \/PRNewswire\/ &#8211; Valeo Pharma Inc. (CSE: VPH)\u00a0(OTCQB: VPHIF)\u00a0(FSE: VP2) (&#8220;Valeo&#8221; or the &#8220;Company&#8220;), a Canadian pharmaceutical company, today announced that it has entered into a Product Listing Agreement (&#8220;PLA&#8221;) with the Executive Officer of the Ontario Public Drug Program for the listing of\u00a0Redesca\u00ae\u00a0and Redesca HP\u00ae, its low molecular weight heparin (&#8220;LMWH&#8221;) biosimilar, on the Ontario Drug Benefit Formulary effective April 30, 2021. \u00a0 &#8220;With Ontario representing 37% of the Canadian market for LMWHs, the listing of Redesca on the Ontario public formulary is a key milestone for the Redesca commercialization program&#8221;, said Frederic Fasano, President and COO &hellip; Continue reading &quot;Valeo Pharma&#8217;s Redesca\u00ae and Redesca HP\u00ae to Be Covered Under the Ontario Public Drug Benefit Program&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-28T11:05:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO58339&amp;sd=2021-04-28\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Valeo Pharma&#8217;s Redesca\u00ae and Redesca HP\u00ae to Be Covered Under the Ontario Public Drug Benefit Program\",\"datePublished\":\"2021-04-28T11:05:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\\\/\"},\"wordCount\":425,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=MO58339&amp;sd=2021-04-28\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\\\/\",\"name\":\"Valeo Pharma's Redesca\u00ae and Redesca HP\u00ae to Be Covered Under the Ontario Public Drug Benefit Program - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=MO58339&amp;sd=2021-04-28\",\"datePublished\":\"2021-04-28T11:05:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=MO58339&amp;sd=2021-04-28\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=MO58339&amp;sd=2021-04-28\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Valeo Pharma&#8217;s Redesca\u00ae and Redesca HP\u00ae to Be Covered Under the Ontario Public Drug Benefit Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valeo Pharma's Redesca\u00ae and Redesca HP\u00ae to Be Covered Under the Ontario Public Drug Benefit Program - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/","og_locale":"en_US","og_type":"article","og_title":"Valeo Pharma's Redesca\u00ae and Redesca HP\u00ae to Be Covered Under the Ontario Public Drug Benefit Program - Market Newsdesk","og_description":"PR Newswire Ontario represents 37% of the Canadian low molecular weight heparin market Additional provincial coverage expected to follow MONTREAL, April 28, 2021 \/PRNewswire\/ &#8211; Valeo Pharma Inc. (CSE: VPH)\u00a0(OTCQB: VPHIF)\u00a0(FSE: VP2) (&#8220;Valeo&#8221; or the &#8220;Company&#8220;), a Canadian pharmaceutical company, today announced that it has entered into a Product Listing Agreement (&#8220;PLA&#8221;) with the Executive Officer of the Ontario Public Drug Program for the listing of\u00a0Redesca\u00ae\u00a0and Redesca HP\u00ae, its low molecular weight heparin (&#8220;LMWH&#8221;) biosimilar, on the Ontario Drug Benefit Formulary effective April 30, 2021. \u00a0 &#8220;With Ontario representing 37% of the Canadian market for LMWHs, the listing of Redesca on the Ontario public formulary is a key milestone for the Redesca commercialization program&#8221;, said Frederic Fasano, President and COO &hellip; Continue reading \"Valeo Pharma&#8217;s Redesca\u00ae and Redesca HP\u00ae to Be Covered Under the Ontario Public Drug Benefit Program\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-28T11:05:11+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO58339&amp;sd=2021-04-28","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Valeo Pharma&#8217;s Redesca\u00ae and Redesca HP\u00ae to Be Covered Under the Ontario Public Drug Benefit Program","datePublished":"2021-04-28T11:05:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/"},"wordCount":425,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO58339&amp;sd=2021-04-28","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/","name":"Valeo Pharma's Redesca\u00ae and Redesca HP\u00ae to Be Covered Under the Ontario Public Drug Benefit Program - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO58339&amp;sd=2021-04-28","datePublished":"2021-04-28T11:05:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO58339&amp;sd=2021-04-28","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO58339&amp;sd=2021-04-28"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Valeo Pharma&#8217;s Redesca\u00ae and Redesca HP\u00ae to Be Covered Under the Ontario Public Drug Benefit Program"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/483076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=483076"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/483076\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=483076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=483076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=483076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}